Pharma-Bio Serv, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pharma-Bio Serv, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $9.00M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $9.51M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $16.98M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $19.40M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $20.12M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $21.56M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $19.51M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $17.80M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $13.30M | Jan 29, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.91M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $2.52M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $5.07M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $4.88M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $5.36M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $6.67M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $6.18M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $5.69M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $3.84M | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $5.78M | Jan 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($100.5K) | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | ($777.6K) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $1.31M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $1.01M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($2.09M) | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $2.05M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $2.09M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $1.28M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | ($1.41M) | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | ($256.6K) | Jan 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($637.7K) | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | ($1.29M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $1.12M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $1.17M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($3.85M) | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $2.23M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $1.70M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | ($1.26M) | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | ($777.8K) | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | ($91.8K) | Jan 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $3.55M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $3.80M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $3.95M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $3.71M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $9.21M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $4.44M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $4.48M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $4.60M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $4.66M | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $5.87M | Jan 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($214.9K) | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | ($566.7K) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $1.89M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $592.5K | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $804.8K | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $1.51M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | ($2.21M) | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $3.72M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | ($922.7K) | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $709.7K | Jan 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $6.6K | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $159.7K | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $7.3K | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $19.3K | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $10.8K | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $55.7K | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $57.4K | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $122.0K | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $57.0K | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $1.81M | Jan 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $13.65M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $16.29M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $19.90M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $20.65M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $23.92M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $29.92M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $26.63M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $25.38M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $22.35M | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $24.00M | Jan 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.74M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $2.58M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $3.78M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $4.09M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $5.01M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $7.20M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $6.03M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $5.11M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $1.60M | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $2.19M | Jan 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $11.91M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $13.72M | Jan 29, 2026 |
| FY2025 | Oct 31, 2023 | $16.13M | Jan 29, 2026 |
| FY2024 | Oct 31, 2022 | $16.56M | Jan 29, 2025 |
| FY2023 | Oct 31, 2021 | $18.91M | Jan 29, 2024 |
| FY2022 | Oct 31, 2020 | $22.72M | Jan 30, 2023 |
| FY2021 | Oct 31, 2019 | $20.61M | Feb 11, 2022 |
| FY2020 | Oct 31, 2018 | $20.26M | Feb 1, 2021 |
| FY2019 | Oct 31, 2017 | $20.75M | Jan 29, 2020 |
| FY2018 | Oct 31, 2016 | $21.81M | Jan 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $10.53M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $12.35M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $14.85M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $15.27M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $17.71M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $21.52M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | $19.47M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | $19.11M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | $19.56M | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | $20.98M | Jan 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 31, 2022 | $14.46M | Jan 30, 2023 |
| FY2022 | Oct 31, 2021 | $17.47M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $17.14M | Feb 11, 2022 |
| FY2021 | Oct 31, 2019 | $15.49M | Feb 11, 2022 |
| FY2020 | Oct 31, 2018 | $16.03M | Feb 1, 2021 |
| FY2019 | Oct 31, 2017 | $11.59M | Jan 29, 2020 |
| FY2018 | Oct 31, 2016 | $13.77M | Jan 29, 2019 |
| FY2017 | Oct 31, 2015 | $14.89M | Jan 29, 2018 |
| FY2016 | Oct 31, 2014 | $15.09M | Jan 31, 2017 |
| FY2015 | Oct 31, 2013 | $12.05M | Jan 29, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Oct 31, 2017 | 0 | Jan 29, 2018 |
| FY2017 | Oct 31, 2016 | 0 | Jan 29, 2018 |
| FY2016 | Oct 31, 2015 | 0 | Jan 31, 2017 |
| FY2015 | Oct 31, 2014 | 0 | Jan 29, 2016 |
| FY2014 | Oct 31, 2013 | 0 | Jan 29, 2015 |
| FY2013 | Oct 31, 2012 | 0 | Jan 29, 2014 |
| FY2012 | Oct 31, 2011 | 0 | Jan 29, 2013 |
| FY2011 | Oct 31, 2010 | 0 | Jan 31, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 0 | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 29, 2025 |
| FY2017 | Oct 31, 2017 | 0 | Jan 29, 2018 |
| FY2017 | Oct 31, 2016 | 0 | Jan 29, 2018 |
| FY2016 | Oct 31, 2015 | 0 | Jan 31, 2017 |
| FY2015 | Oct 31, 2014 | 0 | Jan 29, 2016 |
| FY2014 | Oct 31, 2013 | 0 | Jan 29, 2015 |
| FY2013 | Oct 31, 2012 | 0 | Jan 29, 2014 |
| FY2012 | Oct 31, 2011 | 0 | Jan 29, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 22.91M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 22.96M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | 22.96M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | 22.94M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | 23.00M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | 23.00M | Feb 11, 2022 |
| FY2020 | Oct 31, 2019 | 23.00M | Feb 1, 2021 |
| FY2019 | Oct 31, 2018 | 23.06M | Jan 29, 2020 |
| FY2018 | Oct 31, 2017 | 23.09M | Jan 29, 2019 |
| FY2017 | Oct 31, 2016 | 23.01M | Jan 29, 2018 |